Valuation: Rhythm Pharmaceuticals, Inc.

Market Cap 6.37B 5.71B 5.25B 4.76B 8.89B 605B 9.06B 62.62B 25.14B 318B 23.92B 23.41B 1,004B P/E 2026 *
-31.6x
P/E 2027 * -166x
Enterprise Value 6.09B 5.45B 5.02B 4.54B 8.49B 578B 8.65B 59.81B 24.01B 304B 22.85B 22.36B 959B EV / Sales 2026 *
19.3x
EV / Sales 2027 * 10.5x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week+3.70%
1 month-2.78%
3 months-6.73%
6 months+13.78%
Current year-13.52%
1 week 88.72
Extreme 88.72
95.6
1 month 85.38
Extreme 85.38
95.6
Current year 74.5
Extreme 74.5
119.75
1 year 74.5
Extreme 74.5
122.2
3 years 23.26
Extreme 23.26
122.2
5 years 3.04
Extreme 3.04
122.2
10 years 3.04
Extreme 3.04
122.2
Manager TitleAgeSince
Chief Executive Officer 71 2020-07-19
Chief Executive Officer 58 2020-03-27
Chief Tech/Sci/R&D Officer - 2026-08-16
Director TitleAgeSince
Director/Board Member 69 2015-03-31
Chairman 71 2017-04-10
Director/Board Member 71 2015-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Exercice

Chief Executive Officer

150,000 0.2179%
8/31/26 Exercice

Chief Financial Officer

177,148 0.2573%
8/17/26 Free

Chief Technology Officer

75,000 0.1093%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%+3.70%-18.63%+300.56% 6.37B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.82%+5.68%+40.06%+106.16% 426.83B
Weighted average by Cap. +2.00%+6.59%+50.41%+100.73%

Financials

2026 *2027 *
Net sales 315M 282M 260M 235M 440M 29.93B 448M 3.1B 1.24B 15.75B 1.18B 1.16B 49.66B 565M 506M 466M 422M 788M 53.66B 803M 5.55B 2.23B 28.23B 2.12B 2.08B 89.01B
Net income -204M -182M -168M -152M -284M -19.34B -290M -2B -803M -10.17B -765M -748M -32.09B -31.17M -27.91M -25.68M -23.26M -43.49M -2.96B -44.3M -306M -123M -1.56B -117M -114M -4.91B
Net Debt -285M -256M -235M -213M -398M -27.11B -406M -2.8B -1.13B -14.26B -1.07B -1.05B -44.97B -466M -418M -384M -348M -651M -44.29B -663M -4.58B -1.84B -23.3B -1.75B -1.71B -73.48B
Projected Income Statement - Annual - Rhythm Pharmaceuticals, Inc.
Logo Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
Employees
414
Date Price Change Volume
26-10-30 US$92.57 -0.54% 431,656
26-10-29 US$93.07 +1.20% 760,468
26-10-28 US$91.97 -0.23% 533,872
26-10-27 US$92.18 +3.03% 400,169
26-10-26 US$89.47 +0.22% 289,449
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Rhythm Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
92.57USD
Average target price
140.53USD
Spread / Average Target
+51.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rhythm Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RYTM Stock